Compare GDC & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDC | NTHI |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.3M | 243.9M |
| IPO Year | N/A | N/A |
| Metric | GDC | NTHI |
|---|---|---|
| Price | $3.11 | $10.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.4K | ★ 69.4K |
| Earning Date | 03-17-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | N/A | ★ $59,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.42 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.03 | $3.20 |
| 52 Week High | $9.92 | $25.00 |
| Indicator | GDC | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 33.15 | 57.79 |
| Support Level | $3.10 | $9.05 |
| Resistance Level | $3.78 | $11.38 |
| Average True Range (ATR) | 0.37 | 1.16 |
| MACD | -0.09 | 0.11 |
| Stochastic Oscillator | 0.63 | 57.54 |
GD Culture Group Ltd focuses its business on two segments mainly through the Company and two subsidiaries. 1) AI-driven digital human creation and customization; 2) Live streaming and e-commerce. The company has relentlessly been focusing on serving its customers and creating value for them through the continual innovation and optimization of its products and services. For the AI-driven digital human creation and customization sector, the Company uses AI algorithms and software to generate realistic 3D or 2D digital human models. AI algorithms and machine learning models are used to simulate human characteristics, such as facial expressions, body movements, and even speech patterns.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).